By Donna Loyle, communications manager, LIMR
Main Line Health is participating in several clinical trials that are testing devices to treat tricuspid regurgitation (TR), a condition in which blood flows through the tricuspid valve in the wrong direction during part of the cardiac cycle.
- CLASP TR is a single-arm, early feasibility study testing the Edwards PASCAL transcatheter valve repair system. Participants have the PASCAL system implanted and then are assessed for up to five years post procedure. Eligible patients are those with severe functional or degenerative TR. For more: www.mainlinehealth.org/research/clinical-trials/clasp-tr-efs
- CLASP II TR is a randomized trial to evaluate transcatheter tricuspid valve repair with the Edwards PASCAL system and optimal medical therapy (OMT) vs. OMT alone in patients with severe TR. Eligible participants must be symptomatic, New York Heart Association (NYHA) class II-IVa or were hospitalized for heart failure in the past 12 months. For more: www.mainlinehealth.org/research/clinical-trials/clasp-ii-tr
- Cardioband is a single-arm early feasibility study testing the Edwards Cardioband tricuspid valve reconstruction system. Eligible patients must have chronic TR graded as moderate or greater, and must be symptomatic despite medical therapy (patient must be on diuretic therapy). For more: www.mainlinehealth.org/research/clinical-trials/cardioband
Each of these trials has inclusion and exclusion criteria, so check the above-noted websites for more information, as well as contact information for the clinical trial coordinator.